Kong et al. demonstrated that the use of the Fuzheng Jiedu Quyu (FJQR) formula in combination with CAP-based chemotherapy in a cohort of 129 patients with HER-2-negative GC reduced the incidence of grade 3–4 ADRs, including leukopenia, anaemia, and thrombocytopenia, compared with placebo (p < 0.05) [26]. The gene discussed is ERBB2; the disease is Thrombocytopenia.